LLY
1,023.96
+0.31%↑
JNJ
196.01
+0.34%↑
ABBV
232.37
0%↓
UNH
321.37
-3.25%↓
AZN
89.14
+0.64%↑
LLY
1,023.96
+0.31%↑
JNJ
196.01
+0.34%↑
ABBV
232.37
0%↓
UNH
321.37
-3.25%↓
AZN
89.14
+0.64%↑
LLY
1,023.96
+0.31%↑
JNJ
196.01
+0.34%↑
ABBV
232.37
0%↓
UNH
321.37
-3.25%↓
AZN
89.14
+0.64%↑
LLY
1,023.96
+0.31%↑
JNJ
196.01
+0.34%↑
ABBV
232.37
0%↓
UNH
321.37
-3.25%↓
AZN
89.14
+0.64%↑
LLY
1,023.96
+0.31%↑
JNJ
196.01
+0.34%↑
ABBV
232.37
0%↓
UNH
321.37
-3.25%↓
AZN
89.14
+0.64%↑
24h
Current
Min
Max
Income | -75M -544K |
|---|---|
Sales | 182K 26M |
P/E Sector Avg | 19.362 105.69 |
Profit margin | -2.087 |
Employees | 59 |
EBITDA | 75M 4.1M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +155.32% upside |
Market Cap | -61M 512M |
|---|---|
Previous open | 0 |
Previous close | 0 |
Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.
27 lut 2025, 15:29 UTC
Zevra Therapeutics to Sell Priority-Review Voucher for $150 Million
DJ
Read
Price change
By TipRanks
12 Months Forecast
Average 24 USD 155.32%
High 26 USD
Low 21 USD
Based on 6 Wall Street analysts offering 12 month price targets forKemPharm Inc - Dist in the last 3 months.
By TipRanks
Strong Buy
6 ratings
6
Buy
0
Hold
0
Sell
Based on 6 analysts giving stock ratings to KemPharm Inc - Dist in the past 3 months.
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$